In addition to its non-target effects on the disease targets FOXM1 and MADD [24], risperdal also targets the 5′-splice site and GA-rich sequence, located 24 nucleotides upstream, for SMA treatment [25]. The gene discussed is MADD; the disease is proximal spinal muscular atrophy.